On Aug. 30, 2021, OPKO announced completion of enrollment in its Phase 2 trial with RAYALDEEﾮ as a treatment for mild-to-moderate COVID-19. The U.S. trial was expected to enroll approximately 160 subjects, including some with stage 3 or 4 chronic kidney disease who are at higher risk for developing more severe illness. Final enrollment reached 171 subjects and topline data was expected later in 2021.